Clinical trial NCT06728150: Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer
Official title: Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Breast Cancer Metastatic
Brain Metastasases
Keywords: Breast cancer brain metastases
Lead sponsor: Monash University
Sponsor class: OTHER
Collaborators: name: The Alfred
name: Breast Cancer Trials, Australia and New Zealand
First posted: 2024-12-11
Enrollment: 45
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a diagnosis of metastatic breast cancer.

Brief summary: The purpose of this study is to improve outcome of breast cancer patients who develop brain metastases. This will investigate the benefits of early detection of brain metastases using brain imaging.

In patients diagnosed and currently being treated for advanced or metastatic breast cancer, current guidelines do not recommend routine brain imaging. However, there is emerging evidence suggesting that patients diagnosed without symptoms of brain metastases may have a better outcome than those with symptoms such as headache, vomiting and weakness.

In current practice, if signs and symptoms suggestive of brain metastases are to develop, then the doctor will arrange imaging of the brain, which may be a computerised tomography (CT scan) and/or a magnetic resonance imaging (MRI) scan. Should brain metastasis be detected, local radiotherapy, chemotherapy or targeted treatments will be offered.

When initially diagnosed with metastatic or advanced breast cancer, participant will or would have undergone a brain scan by either MRI or CT during normal standard full-body CT scan (chest, abdomen and pelvis) imaging. In this study, each time participants have a regular full-body CT scans to assess treatment progress, they will also have an additional CT scan of the brain.

Participants will have a total of 12 extra brain scans, with scans taking place every three months for the first 2 years, and every 6 months for the following years. These scans will occur at the same location as your current treatment. There will be no extra costs involved in the study and participants will be in the study for 4 years and following their follow-up details will be collected from medical records.

Some participants who develop brain metastases during the followup will have neurosurgery to remove these metastases. The investigators will collect either fresh or archived tissues and a cerebrospinal fluid (CSF) sample at the time of surgery from those patients.

If the treating investigators do not think neurosurgery is an option, they will ask participants to have a lumbar puncture for the collection of CSF. The purpose of this optional CSF collection is to take a liquid biopsy to check for markers (or biomarkers) potentially expressed by the breast cancer tumour cells in the brain. Participants will also be asked to provide a blood sample as well as old tumour from breast surgery (other metastatic tumour tissue).

The information obtained from this component of the study will not impact a parcipants current management, but it will help researchers to develop better treatments for breast cancer brain metastases in the future.


Eligibility criteria: Inclusion Criteria:

* Metastatic breast cancer with visceral, nodal or bone metastasis
* Human epidermal growth factor type2 (HER2-positive disease)
* Triple negative breast cancer (TNBC) with metastatic disease
* Oestrogen Receptor Positive disease (ER-positive disease) after second-line therapy and cyclin dependent kinase 4/6 inhibitors (CDK4/6 inhibitors), plus more than two sites of bone metastasis or visceral metastasis
* Diagnosis of metastatic disease in the last 3 months and free of symptoms or disease (with brain MRI confirmation) • Medicare Eligible

Exclusion Criteria:

* Symptomatic brain metastasis
* Inability to provide consent
* Inadequate organ function
* Pregnancy.

Primary outcomes:
measure: Incidence of screen-detected asymptomatic brain metastasis.
timeFrame: 12 months
Secondary outcomes:
measure: Incidence of symptomatic brain metastases
timeFrame: Though to study completion, an average of 1 year
measure: Progression free survival
timeFrame: Though to study completion, an average of 1 year
measure: Overall survival
timeFrame: Though to study completion, an average of 1 year
measure: Number of surgical resections
timeFrame: Though to study completion, an average of 1 year
measure: Rate of stereotactic radiotherapy
timeFrame: Though to study completion, an average of 1 year
measure: Evaluation of the role of early treatment on intracranial disease control
timeFrame: Though to study completion, an average of 1 year
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: The Alfred
state: Victoria
Study officials:
affiliation: Associate Professor and Medical Oncologist
name: Mahesh Iddawela, MBBS FRACP PhD
role: PRINCIPAL_INVESTIGATOR
References: